βγ G-proteins, but not regulators of G-protein signaling 4, modulate opioid-induced respiratory rate depression. [PDF]
Danaf J +2 more
europepmc +1 more source
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim +17 more
wiley +1 more source
Heterotrimeric G-proteins and cAMP regulate gene expression during growth on cellulose in <i>Neurospora crassa</i>. [PDF]
Collier L +5 more
europepmc +1 more source
Structural basis of adhesion GPCR GPR110 activation by stalk peptide and G-proteins coupling. [PDF]
Zhu X +11 more
europepmc +1 more source
Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim +11 more
wiley +1 more source
Function of heterotrimeric G-proteins in plant development
Heterotrimeric G-proteins act as signal transducers in all eukaryote cells. They transduce and amplify extracellular signals sensed by integral membrane receptors to various downstream intracellular effectors.
Sochor, Vít
core
RSV Vaccines: Targeting Prefusion F and G Proteins from Structural Design to Clinical Application. [PDF]
Yu D +8 more
europepmc +1 more source
Polyisoprenylated cysteinyl amide inhibitors deplete singly polyisoprenylated monomeric G-proteins in lung and breast cancer cell lines. [PDF]
Tawfeeq N +4 more
europepmc +1 more source
Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba +5 more
wiley +1 more source
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David +12 more
wiley +1 more source

